Renal clearance of TMAO

Biomarker1 paper1 finding

Human trial1

Interventions

1

Dapagliflozin

downin humans1Moderate certainty

1 study

Dapagliflozin decreases renal clearance of TMAO in humans (22.6% lower, p = 0.025).
Human trialType 2 diabetesn = 54
Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes · Endocrinology, diabetes & metabolism · 1 Oct 2026

Dapagliflozin →

Latest

1

Endocrinology, Diabetes & MetabolismHuman trial1 Oct

Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes